Refine
Has Fulltext
- yes (27)
Is part of the Bibliography
- yes (27)
Year of publication
Document Type
- Journal article (27)
Language
- English (27)
Keywords
- T cells (4)
- GvHD (2)
- Multiple myeloma (2)
- alloreactive T cells (2)
- cancer (2)
- immune cells (2)
- mouse models (2)
- regulatory T cells (2)
- Activation (1)
- Allogeneic stem cell transplantation (1)
Institute
- Medizinische Klinik und Poliklinik II (25)
- Pathologisches Institut (7)
- Institut für Virologie und Immunbiologie (6)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (5)
- Kinderklinik und Poliklinik (5)
- Graduate School of Life Sciences (4)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Rudolf-Virchow-Zentrum (3)
- Neurochirurgische Klinik und Poliklinik (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Frauenklinik und Poliklinik (1)
- Institut für Experimentelle Biomedizin (1)
- Institut für Molekulare Infektionsbiologie (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Julius-von-Sachs-Institut für Biowissenschaften (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (1)
- Lehrstuhl für Orthopädie (1)
- Medizinische Klinik und Poliklinik I (1)
- Neurologische Klinik und Poliklinik (1)
- Physikalisches Institut (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 825575 (1)
Background
Acute graft-versus-host disease (aGVHD) poses a major limitation for broader therapeutic application of allogeneic hematopoietic cell transplantation (allo-HCT). Early diagnosis of aGVHD remains difficult and is based on clinical symptoms and histopathological evaluation of tissue biopsies. Thus, current aGVHD diagnosis is limited to patients with established disease manifestation. Therefore, for improved disease prevention it is important to develop predictive assays to identify patients at risk of developing aGVHD. Here we address whether insights into the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T cells before clinical aGVHD onset to permit for efficient therapeutic intervention.
Methods
Murine major histocompatibility complex (MHC) mismatched and minor histocompatibility antigen (miHAg) mismatched allo-HCT models were employed to assess the spatiotemporal distribution of donor T cells with flow cytometry and in vivo bioluminescence imaging (BLI). Daily flow cytometry analysis of peripheral blood mononuclear cells allowed us to identify migrating alloreactive T cells based on homing receptor expression profiles.
Results
We identified a time period of 2 weeks of massive alloreactive donor T cell migration in the blood after miHAg mismatch allo-HCT before clinical aGVHD symptoms appeared. Alloreactive T cells upregulated α4β7 integrin and P-selectin ligand during this migration phase. Consequently, targeted preemptive treatment with rapamycin, starting at the earliest detection time of alloreactive donor T cells in the peripheral blood, prevented lethal aGVHD.
Conclusions
Based on this data we propose a critical time frame prior to the onset of aGVHD symptoms to identify alloreactive T cells in the peripheral blood for timely and effective therapeutic intervention.